Pharmacotherapeutics of GOUT

 

1. Definition

• Gout is a metabolic disorder caused by hyperuricemia and deposition of monosodium urate (MSU) crystals in joints and tissues.
• It produces episodes of acute inflammatory arthritis, followed by symptom-free periods.
• Repeated attacks may lead to chronic tophaceous gout, joint destruction, and renal complications.
• The great toe is commonly affected, producing podagra.

2. Etiology and Risk Factors

A. Increased production of uric acid

• Excessive purine metabolism.
• High intake of purine-rich foods.
• Excessive alcohol consumption.
• High fructose intake.
• Increased cell destruction, e.g., malignancy or chemotherapy.
• Genetic abnormalities affecting purine metabolism.

B. Decreased excretion of uric acid

• Chronic kidney disease.
• Renal tubular abnormalities.
• Dehydration.
• Use of certain drugs.

C. Important risk factors

• Obesity.
• Metabolic syndrome.
• Hypertension.
• Diabetes mellitus.
• Chronic kidney disease.
• High-purine diet.
• Alcohol consumption.
• Family history of gout.
• Older age.
• Certain drugs, particularly:
• Thiazide diuretics.
• Loop diuretics.
• Low-dose aspirin.
• Cyclosporine.
• Tacrolimus.

3. Pathophysiology

• Purines are metabolized to hypoxanthine.
• Hypoxanthine is converted to xanthine.
• Xanthine is converted to uric acid by the enzyme xanthine oxidase.
• Humans do not possess functional uricase, so uric acid is the final product of purine metabolism.
• When serum urate becomes excessively high, MSU crystals may form.
• These crystals deposit in joints and tissues.
• Crystal deposition activates the innate immune system.
• Activation of the NLRP3 inflammasome promotes formation of IL-1β.
• IL-1β and other inflammatory mediators recruit neutrophils.
• Neutrophil activation produces intense inflammation.
• This causes:
• Severe pain.
• Redness.
• Swelling.
• Warmth.
• Restricted joint movement.

4. Clinical Manifestations

Acute gout

• Sudden onset of severe joint pain.
• Usually begins at night or early morning.
• Joint swelling.
• Redness.
• Increased temperature of the affected joint.
• Extreme tenderness.
• Difficulty moving the joint.
• Commonly affects the first metatarsophalangeal joint.

Chronic gout

• Recurrent acute attacks.
• Persistent joint inflammation.
• Formation of tophi.
• Joint deformity.
• Joint destruction.
• Reduced mobility.

Renal manifestations

• Uric acid kidney stones.
• Uric acid nephropathy.
• Possible progression of renal impairment.

5. Diagnosis

• Serum uric acid: useful for assessment but may be normal during an acute attack.
• Synovial fluid examination: definitive diagnosis is based on identification of needle-shaped, negatively birefringent MSU crystals under polarized microscopy.
• CBC and inflammatory markers may support assessment.
• Serum creatinine and renal function should be assessed.
• Liver function may be monitored when appropriate.
• Joint imaging may show:
• Erosions.
• Tophi.
• Joint damage.
• Ultrasound may demonstrate the double-contour sign.

6. Goals of Pharmacotherapy

The major objectives are:

• Rapidly relieve pain during an acute attack.
• Suppress joint inflammation.
• Prevent recurrent gout attacks.
• Reduce serum urate concentration.
• Dissolve existing urate crystals.
• Reduce or eliminate tophi.
• Prevent joint destruction.
• Prevent uric acid kidney stones.
• Preserve renal function.
• Improve quality of life.

Serum urate target

• General target: <6 mg/dL.
• More severe tophaceous gout may require a lower target, often <5 mg/dL, depending on clinical guidelines and individual circumstances.

7. Treatment of Acute Gout

The main drugs are:

• NSAIDs
• Colchicine
• Corticosteroids
• Selected cases: IL-1 inhibitors

Treatment should ideally begin as soon as possible after the onset of symptoms.

8. NSAIDs

Examples

• Indomethacin.
• Naproxen.
• Ibuprofen.
• Diclofenac.
• Other appropriate NSAIDs.

Mechanism of action

• NSAIDs inhibit COX enzymes.
• This decreases prostaglandin synthesis.
• Reduction in prostaglandins decreases inflammation and pain.

Uses

• First-line option for many patients with acute gout.
• Particularly useful when started early.

Adverse effects

• Gastric irritation.
• Dyspepsia.
• Peptic ulceration.
• Gastrointestinal bleeding.
• Renal impairment.
• Fluid retention.
• Increased blood pressure.
• Cardiovascular adverse effects.

Contraindications/cautions

• Severe renal impairment.
• Active peptic ulcer disease.
• Significant gastrointestinal bleeding.
• Severe heart failure.
• Certain cardiovascular conditions.
• NSAID hypersensitivity.

9. Colchicine

Mechanism of action

• Colchicine binds to tubulin.
• It inhibits microtubule polymerization.
• This reduces neutrophil migration and activation.
• Therefore, it suppresses the inflammatory response to MSU crystals.

Uses

• Acute gout attack.
• Prevention of gout flares during initiation of urate-lowering therapy.

Adverse effects

• Diarrhea.
• Nausea.
• Vomiting.
• Abdominal pain.
• Muscle toxicity.
• Bone marrow suppression in severe toxicity.
• Peripheral neuropathy in prolonged or excessive exposure.

Precautions

• Renal impairment.
• Hepatic impairment.
• Elderly patients.
• Important drug interactions, particularly with strong CYP3A4/P-glycoprotein inhibitors.

10. Corticosteroids

Examples

• Prednisone/prednisolone.
• Methylprednisolone.
• Triamcinolone.

Routes

• Oral.
• Intra-articular.
• Intravenous in selected situations.

Mechanism

• Corticosteroids suppress multiple inflammatory pathways.
• They decrease production of inflammatory mediators and cytokines.
• This rapidly reduces inflammation.

Uses

• Acute gout.
• Particularly useful when NSAIDs or colchicine are unsuitable.
• Intra-articular corticosteroids are useful when one or a few joints are involved.

Adverse effects

• Hyperglycemia.
• Hypertension.
• Fluid retention.
• Mood changes.
• Increased infection risk.
• Gastrointestinal effects.

11. IL-1 Inhibitors

Examples

• Anakinra.
• Canakinumab.

Mechanism

• IL-1 plays an important role in MSU crystal-induced inflammation.
• IL-1 inhibitors reduce this inflammatory response.

Uses

• Selected patients with severe or recurrent gout who cannot use conventional treatments.

Limitations

• High cost.
• Infection risk.
• Limited routine use.
• Availability may vary.

12. Urate-Lowering Therapy

Urate-lowering therapy is used for long-term prevention, not primarily for immediate pain relief.

Important indications include:

• Recurrent gout attacks.
• Tophi.
• Gout-related joint damage.
• Certain patients with uric acid kidney stones.
• Severe or chronic gout.

Main classes include:

• Xanthine oxidase inhibitors
• Allopurinol.
• Febuxostat.
• Uricosuric drugs
• Probenecid.
• Uricase therapy
• Pegloticase.

13. Allopurinol

Drug class

• Xanthine oxidase inhibitor.

Mechanism

• Allopurinol is converted to an active metabolite, oxypurinol.
• It inhibits xanthine oxidase.
• This decreases conversion of hypoxanthine and xanthine into uric acid.
• Therefore, uric acid production decreases.

Importance

• Generally considered the preferred first-line urate-lowering therapy for most patients.

Administration principle

• Start with a low dose.
• Gradually increase the dose according to serum urate response and patient factors.
• Renal function should be considered.

Adverse effects

• Skin rash.
• Nausea.
• Liver enzyme abnormalities.
• Rare but serious allopurinol hypersensitivity syndrome.
• Severe cutaneous adverse reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis can rarely occur.

Important precaution

• HLA-B*58:01 testing may be recommended before starting allopurinol in selected high-risk populations according to local guidelines.

14. Febuxostat

Drug class

• Non-purine selective xanthine oxidase inhibitor.

Mechanism

• Inhibits xanthine oxidase.
• Decreases conversion of xanthine and hypoxanthine into uric acid.
• Reduces serum urate concentration.

Uses

• Patients who cannot tolerate allopurinol.
• Patients in whom allopurinol is inadequate or unsuitable.

Adverse effects

• Nausea.
• Rash.
• Liver enzyme abnormalities.
• Gout flares during initiation.

Precaution

• Cardiovascular risk should be carefully considered, particularly in patients with established cardiovascular disease.

15. Uricosuric Drugs

Example

• Probenecid

Mechanism

• Inhibits renal tubular reabsorption of uric acid.
• Increases urinary excretion of uric acid.
• Therefore, serum urate concentration decreases.

Uses

• Selected patients who have inadequate renal urate excretion.
• Patients with sufficient renal function.

Adverse effects

• Gastrointestinal irritation.
• Rash.
• Increased risk of uric acid kidney stones.

Contraindications/cautions

• Significant renal impairment.
• History of uric acid kidney stones.
• Adequate hydration should be maintained.

16. Pegloticase

Drug class

• Recombinant uricase.

Mechanism

• Converts uric acid into allantoin.
• Allantoin is much more soluble and is easily eliminated by the kidneys.
• Produces a marked reduction in serum urate.

Uses

• Severe, chronic, refractory gout.
• Patients who do not respond adequately to conventional urate-lowering therapy.

Adverse effects

• Infusion reactions.
• Hypersensitivity reactions.
• Risk of severe reactions if treatment is continued despite loss of urate-lowering response.

17. Flare Prophylaxis During Urate-Lowering Therapy

• Starting urate-lowering therapy can temporarily trigger gout flares.
• This occurs because changing urate levels can mobilize existing MSU crystals.
• Therefore, anti-inflammatory prophylaxis is commonly used during initiation.

Options

• Low-dose colchicine.
• Low-dose NSAID when appropriate.
• Low-dose corticosteroid in selected patients.

Duration

• Usually continued for several months and longer in patients with ongoing tophi or frequent flares, depending on clinical response and guideline recommendations.

---

18. Important Point During Acute Attack

• If a patient is already taking allopurinol or another urate-lowering drug, it is generally continued during an acute gout attack.
• The acute attack should be treated separately with an appropriate anti-inflammatory drug.
• Urate-lowering therapy should not be abruptly stopped simply because an acute attack occurs.

19. Non-Pharmacological Management

Dietary modification

• Reduce excessive intake of:
• Red meat.
• Organ meat.
• Certain seafood.
• High-purine foods.
• Reduce sugar-sweetened beverages.
• Reduce excessive fructose intake.
• Avoid or limit excessive alcohol consumption, particularly beer.

Lifestyle modification

• Maintain healthy body weight.
• Regular physical activity.
• Adequate hydration.
• Avoid crash diets and prolonged fasting.

Management of associated conditions

• Control hypertension.
• Control diabetes.
• Manage obesity.
• Manage dyslipidemia.
• Assess and manage chronic kidney disease.

Medication review

• Identify drugs that increase serum urate where clinically appropriate.
• Thiazide and loop diuretics can increase urate.
• In suitable patients, losartan may be considered because of its uricosuric effect, but antihypertensive selection should primarily consider the patient's overall clinical needs.

20. Treatment Approach in Simple Flow

Acute gout attack → Rapid anti-inflammatory treatment

→ NSAID OR colchicine OR corticosteroid

→ Assess severity, renal function, cardiovascular and gastrointestinal risks

→ Once long-term treatment is indicated → Start urate-lowering therapy

→ Allopurinol generally preferred first-line

→ If unsuitable/intolerant/inadequate response → Febuxostat or appropriate alternative

→ Selected patients → Uricosuric therapy

→ Severe refractory gout → Pegloticase

→ During initiation → Flare prophylaxis

→ Continue treatment and monitor serum urate

→ Maintain target serum urate and prevent recurrent attacks.

21. Monitoring

During treatment, monitor:

• Serum uric acid.
• Renal function.
• Liver function when appropriate.
• Frequency and severity of gout attacks.
• Presence or size of tophi.
• Adverse drug reactions.
• Drug interactions.
• Patient adherence.
• Cardiovascular risk where relevant.

22. Summary

Gout is caused by hyperuricemia and deposition of monosodium urate crystals, producing acute and chronic inflammatory arthritis. The pharmacological treatment has two major components: treatment of acute attacks and long-term urate lowering. Acute attacks are mainly treated with NSAIDs, colchicine, or corticosteroids, while selected refractory cases may require IL-1 inhibition. Long-term treatment aims to maintain serum urate below the target level and is primarily achieved with allopurinol, with febuxostat, uricosuric drugs, or pegloticase used in appropriate patients. Lifestyle modification, adequate hydration, dietary management, control of comorbidities, and prophylaxis against treatment-related flares are important for successful long-term management.

Top of Form

 END OF SLIDE

 

Bottom of Form